Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Topical loperamide

This article was originally published in The Tan Sheet

Executive Summary

SmithKline Beecham and Adolor sign licensing agreement for worldwide (excluding Korea) prescription and OTC development and commercial rights to the topical dermal ingredient ADL 2-1294 (loperamide) used for the treatment of inflammatory pain and itching. If multiple indications for the ingredient are found, Adolor will receive up to $48 mil. from development payments as well as a licensing fee and equity investment from SmithKline. Loperamide is sold as an OTC oral antidiarrhea. The reference product is McNeil Consumer Healthcare's Imodium
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS090149

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel